Marine Bioactive Molecules as Inhibitors of the Janus Kinases: A Comparative Molecular Docking and Molecular Dynamics Simulation Approach. [PDF]
Ahmed EA, Abdelsalam SA.
europepmc +1 more source
“Nomen Omen: The Myth of God Janus”
JEADV Clinical Practice, EarlyView.
Alba Guglielmo
wiley +1 more source
Mechanosensitive Cell‐Laden Shape‐Memory Scaffolds Engineered via Cryogelation
GelMA‐based shape‐memory scaffolds encapsulating human adipose‐derived stem cells are fabricated via cryogelation, showing rapid recovery and high cell viability. Under cyclic compression, they promoted mechanotransduction gene expression, and composite formulations (collagen/GelMA, dECM/GelMA) retained robust shape‐memory, highlighting their promise ...
JaeYoon Lee +4 more
wiley +1 more source
Systematic review of Janus kinases inhibitors for rheumatoid arthritis: methodology, reporting, and quality of evidence evaluation. [PDF]
Shen X +5 more
europepmc +1 more source
Anisodamine Maintains the Stability of Intervertebral Disc Tissue by Inhibiting the Senescence of Nucleus Pulposus Cells and Degradation of Extracellular Matrix via Interleukin-6/Janus Kinases/Signal Transducer and Activator of Transcription 3 Pathway. [PDF]
Tang N, Dong Y, Chen C, Zhao H.
europepmc +1 more source
Adapter Protein Shc Regulates Janus Kinase 3 Phosphorylation [PDF]
Jayshree Mishra, Narendra Kumar
openalex +1 more source
This study investigates the molecular alterations underlying angiotensin II (Ang II)‐induced vascular remodeling in cardiovascular diseases using a multi‐omics approach. Through data exploration and integrated multi‐omics analysis, our findings reveal that Ang II‐driven vascular injury in vascular smooth muscle cells is mediated by metabolic ...
Yiwei Hu +8 more
wiley +1 more source
Sometimes Small Is Beautiful: Discovery of the Janus Kinases (JAK) and Signal Transducer and Activator of Transcription (STAT) Pathways and the Initial Development of JAK Inhibitors for IBD Treatment. [PDF]
Kaunitz JD.
europepmc +1 more source
ABSTRACT Nemolizumab, an anti‐interleukin‐31 receptor A monoclonal antibody, has been approved in Japan for treating atopic dermatitis (AD)‐associated pruritus. While it is effective for itch control, nemolizumab‐associated cutaneous adverse events have been increasingly recognized, yet their clinical features remain poorly characterized. In this study,
Wataru Sasaki +24 more
wiley +1 more source

